HLA-B5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

Nature Genetics

Volumn 41, Issue 7, 2009, Pages 816-819

  Daly, Ann K ^a   Donaldson, Peter T ^a   Bhatnagar, Pallav ^a   Shen, Yufeng ^b   Pe'Er, Itsik ^b   Floratos, Aris ^b   Daly, Mark J ^c   Goldstein, David B ^d   John, Sally ^e   Nelson, Matthew R ^f   Graham, Julia ^a   Park, B Kevin ^g   Dillon, John F ^h   Bernal, William ⁱ   Cordell, Heather J ^a   Pirmohamed, Munir ^g   Aithal, Guruprasad P ^j   Day, Christopher P ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Columbia University ^*  (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DUKE UNIVERSITY   (United States)

^e PFIZER INC   (United States)

^f GLAXOSMITHKLINE   (United States)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

^h UNIVERSITY OF DUNDEE   (United Kingdom)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF NOTTINGHAM   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUCLOXACILLIN; HLA B57 ANTIGEN; HLA B ANTIGEN; HLA B*5701 ANTIGEN, HUMAN; HLA-B*5701 ANTIGEN, HUMAN;

ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HETEROZYGOTE DETECTION; HUMAN; LIVER INJURY; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; FEMALE; GENETIC ASSOCIATION; GENETICS; MALE; TOXIC HEPATITIS;

CASE-CONTROL STUDIES; FEMALE; FLOXACILLIN; GENOME-WIDE ASSOCIATION STUDY; HEPATITIS, TOXIC; HLA-B ANTIGENS; HUMANS; MALE;

EID: 67649859295     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.379     Document Type: Article

References (29)

1. Mann, R. & Andrews, E. (eds.). Pharmacovigilance (John Wiley and Sons, Chichester, 2006).
2. Sgro, C. et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36, 451-455 (2002).
3. Ostapowicz, G. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137, 947-954 (2002).
4. Olsson, R. et al. Liver damage fron flucloxacillin, cloxacillin and dicloxacillin. J. Hepatol. 15, 154-161 (1992).
5. Fairley, C.K., McNeil, J. & Desmond, P. Risk factors for development of flucloxacillin associated jaundice. Br. Med. J. 306, 233-235 (1993).
6. Russmann, S., Kaye, J.A., Jick, S.S. & Jick, H. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br. J. Clin. Pharmacol. 60, 76-82 (2005).
7. Hautekeete, M.L. et al. HLA association of amoxicillin- clavulanate-induced hepatitis. Gastroenterology 117, 1181-1186 (1999).
8. O'Donohue, J. et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47, 717-720 (2000).
9. Kindmark, A. et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8, 186-195 (2008).
10. Lakehal, F. et al. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem. Res. Toxicol. 14, 694-701 (2001).
11. Maria, V.A. & Victorino, R.M. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 41, 534-540 (1997).
12. Danan, G. & Benichou, C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol. 46, 1323-1330 (1993).
13. Novembre, J. et al. Genes mirror geography within Europe. Nature 456, 98-101 (2008).
14. de Bakker, P.I. et al. Practical aspects of imputation-driven meta-analysis of genomewide association studies. Hum. Mol. Genet. 17, R122-R128 (2008).
15. Colombo, S. et al. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J. Infect. Dis. 198, 864-867 (2008).
16. Pachkoria, K. et al. Analysis of IL-10, IL-4 and TNF-a polymorphisms in drug-induced liver injury (DILI) and its outcome. J. Hepatol. 49, 107-114 (2008).
17. Aithal, G.P. et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39, 1430-1440 (2004).
18. Donaldson, P.T. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut 53, 599-608 (2004).
19. Ahmad, T. et al. Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum. Mol. Genet. 12, 647-656 (2003).
20. Browner, W.S. & Newman, T.B. Sample size and power based on the population attributable fraction. Am. J. Public Health 79, 1289-1294 (1989).
21. Bast, B.J. et al. The HB-6, CDw75, and CD76 differentiation antigens are unique cellsurface carbohydrate determinants generated by the b-galactoside a 2,6-sialyltransferase. J. Cell Biol. 116, 423-435 (1992).
22. Hetherington, S. et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23, 1603-1614 (2001).
23. Chessman, D. et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 28, 822-832 (2008).
24. Fellay, J. et al. A whole-genome association study of major determinants for host control of HIV-1. Science 317, 944-947 (2007).
25. Kaplan, H.A., Woloski, B.M., Hellman, M. & Jamieson, J.C. Studies on the effect of inflammation on rat liver and serum sialyltransferase. J. Biol. Chem. 258, 11505-11509 (1983).
26. Nasirikenari, M., Segal, B.H., Ostberg, J.R., Urbasic, A. & Lau, J.T. Altered granulopoietic profile and exaggerated acute neutrophilic inflammation in mice with targeted deficiency in the sialyltransferase ST6Gal I. Blood 108, 3397-3405 (2006).
27. Sutherland, R., Croydon, E.A. & Rolinson, G.N. Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin. BMJ 4, 455-460 (1970).
28. Saxena, R. et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316, 1331-1336 (2007).
29. Willer, C.J. et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat. Genet. 41, 25-34 (2009).